NIPBL

Across TCGA pan-cancer cohorts, NIPBL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NIPBL data layer compared with 26 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher NIPBL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NIPBL expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

COAD, HNSC, and LUAD are the cancer types where NIPBL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	III,IV	0.832	1.000	.029	6	view →
HNSC	DFS	Tertile	III,IV	0.706	0.915	.008	6	view →
LUAD	OS	Tertile	III,IV	0.848	0.337	.003	6	view →
PDAC	DFS	Median	III,IV	0.922	0.496	.047	1	view →
LSCC	DFS	Median	II,III,IV	0.815	0.561	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NIPBL–COAD (DFS)

Open the COAD breakdown →